Skip to main content

Significant investments

Typically, building a strategic position begins by investing in a private company with development potential and expands at follow-on financing rounds as well as IPOs.

HBM Healthcare is committed to broad diversification according to the following parameters: private and public companies; development phase; therapeutic area; geography; company size (market capitalisation, valuation). Without the Board of Directors' approval, the acquisition value of an investment may not exceed 10 percent of net assets.

Overview as at 31 March 2025

CHF
218
million
Shanghai Cathay Biotech
Swixx BioPharma
CHF
210
million
Dren Bio
CHF
79
million
CHF
63
million
Harmony Biosciences
Neurelis
CHF
50
million
Sai Life Sciences
CHF
33
million
CHF
28
million
Fangzhou (Jianke)